Hepatic : - Bilirubin ≤ 1.5 times upper limit of normal for age. - SGPT (ALT) ≤ 3 times institutional upper limit of normal for age. - SGOT (AST) ≤ 3 times institutional upper limit of normal for age. Ability to tolerate PBSC Collection : - No known contraindications to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure. Consent : The patient guardian or patient (if > 18 yrs of age) must consent to all elements of this protocol including surgical resection, the use of resected tumor specimens for RNA preparation, induction chemotherapy and PBSC collection during leukapheresis, high- dose chemotherapy with autologous stem cell res cue (Group A), NMA salvage chemotherapy with autologous stem cell rescue (Group B), and experimental immunotherapy consisting of DC + xALT therapy. Signed informed consent according to institutional guidelines must be obtained prior to Re-MATC H Protocol Page 48 of 106 Version: 20180628 registration. Patients who turn 18 while on t he study will be re -consented at that time using an adult consent form. If subjects are referred from outside physicians and it is not feasible for the subject to travel to a participating site, Tissue Consent can be obtained by telephone from the subject /LAR in accordance with institutional policy, procedure, and/or directive. Additional Eligibility R equirements Prior to Initiation of Consolidation or NMA Chemotherapy: Renal: • GFR of at least 70 ml/min/1.73m 2 (Group A only). Cardiac: • EKG without clinically significant arrhythmias (Group A only) • ECHO cardiogram with an ejection fraction of > 45% or MUGA scan within normal limits (Group A only). Patients in Group B will be eligible if the ejection fraction is < or equal to 45% but will receive Fludarabine only during NMA conditioning prior to vaccine + ALT infusions. Pulmonary: • DLCO, FEV1, FEC (diffusion capacity) > 50% of predicted (corrected for hemoglobin and alveolar volume ). (Group A only) • Crying Vital Capacity if too young to perf orm pulmonary function tests. (Group A only) • Chest X -ray without significant abnormalities and a pulse oximetry reading of ≥ 93% in room air at rest and following a brisk 6 -minute exercise resulting in a target heart rate of at least 100/min. These two tests would be required for any patient in Group A who cannot co-operate for the DLCO test due to neurologic deficits and for all patients in G roup B. Patients in Group B who do not meet this requirement will still be eligible but will receive Fludarabine only during NMA conditioning. 10.2 Exclusion Criteria Disease Status : Patients with clinically significant increased intracranial pressure (e.g., impending herniation), uncontrolled seizures, or requirement for immediate palliative treatment will also be excluded from this study. Concurrent Therapy : Each patient will need to be scheduled for definitive resection or, in select cases, have had surgica l resection and tumor tissue snap frozen and available for TTRNA to be eligible for enrollment. Patients receiving any other concurrent anticancer or investigational drug therapy will be excluded and replaced. Focal boost radiotherapy may be delivered pri or to immunotherapy if required for local control. Pregnancy : Females who are pregnant or need to breast feed during the study period will be excluded. A negative β -HCG test will be required within 2 weeks of enrollment. Patients found to be pregnant will be excluded.